Back | Next |
home / stock / apto / apto message board
Subject | By | Source | When |
---|---|---|---|
Possible reason for Zilo phase 3 trial termination? | dcaf7 | investorshub | 04/07/2023 1:22:22 PM |
Seems like a saga with naked ant-ROR1 antibody | dcaf7 | investorshub | 04/06/2023 10:48:14 PM |
One additional risk shareholders have here is the | Zeppo | investorshub | 04/06/2023 6:41:07 PM |
Most of the market and analyst reports are | Tartiaboy | investorshub | 04/05/2023 3:35:56 PM |
Top 3 Canadian Pharma Stocks of 2023. | dcaf7 | investorshub | 04/05/2023 1:13:18 PM |
They should execute on their own guidance. It | dcaf7 | investorshub | 03/31/2023 10:06:39 PM |
If they are not slow walking Lux, what | Wolverine3 | investorshub | 03/31/2023 7:46:56 PM |
I'm more interested in them getting to the | Tartiaboy | investorshub | 03/31/2023 5:09:39 PM |
In January Corporate presentation you can find, 1Q | dcaf7 | investorshub | 03/29/2023 5:08:22 PM |
I think it will depend on how strong | Tartiaboy | investorshub | 03/29/2023 4:37:34 PM |
ADMIRAL trial was Gilteritinib against salvage therapy in | dcaf7 | investorshub | 03/29/2023 4:30:52 PM |
In the case of TUSP monotherapy I am | Tartiaboy | investorshub | 03/28/2023 3:01:49 PM |
Im going to start praying to St. Jude, | spiderman3600 | investorshub | 03/28/2023 12:28:40 PM |
Would do cartwheels for $8/share | Wolverine3 | investorshub | 03/28/2023 12:54:34 AM |
Canaccord Genuity has decided to maintain its Buy | dcaf7 | investorshub | 03/27/2023 9:06:53 PM |
It should affect Aptose. After that, don't think | dcaf7 | investorshub | 03/25/2023 1:34:23 PM |
That's my point. The design and targets | Tartiaboy | investorshub | 03/24/2023 5:59:48 PM |
Yes, unless they want to recruit Ven-naive patients. | dcaf7 | investorshub | 03/24/2023 5:21:45 PM |
Getting a first look at the population that | Tartiaboy | investorshub | 03/24/2023 4:42:45 PM |
As I previosly mentioned, Tusp/Ven trial won't be | dcaf7 | investorshub | 03/24/2023 4:21:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology com...
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended...
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials Conference Call ...